Page 41 - AN-1-1

Advanced Neurology

SPECIAL FEATURE ARTICLE
Insights on amyloid-related imaging

abnormalities from the “Pre-Alzheimer’s disease
Alliance of China”

Tao-Ran Li , Ying Han 1,2,3,4 *, on behalf of the Pre-AD Alliance of China
1
1 Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China
2 School of Biomedical Engineering, Hainan University, Haikou, 570228, China
3 Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, 100053, China
4 National Clinical Research Center for Geriatric Diseases, Beijing, 100053, China

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and accounts for
60 – 80% of all such cases. For approximately 20 years, the research and development
of new drugs for AD all ended in failure; however, aducanumab was recently granted
accelerated approval by the US Food and Drug Administration. Aducanumab is a
representative passive anti-β-amyloid (Aβ) immunotherapy and is the only approved
drug that directly targets the pathological changes of AD; it can significantly reduce
brain Aβ deposition, which is a hallmark of AD. During the clinical trials of amyloid-
targeting monoclonal antibodies, represented by aducanumab, amyloid-related
imaging abnormalities (ARIA) were the most common and important adverse
reactions. Therefore, before the large-scale clinical application of amyloid-targeting
*Corresponding author: monoclonal antibodies, clinicians and radiologists need to fully understand ARIA
Ying Han (hanying@xwh.ccmu. so that they can make more informed decisions. Considering the very uneven
edu.cn) distribution of medical resources in China, we — on behalf of the “Pre-AD Alliance
Citation: Li T, Han Y, on behalf of of China” — believe that it is necessary to write a consensus to elaborate on the
the Pre-AD Alliance of China, 2022, mechanisms, risk factors, identification methods, and administration processes of
Insights on amyloid-related imaging
abnormalities from the “Pre-AD ARIA.
Alliance of China”. Adv Neuro,
1(1): 2.
https://doi.org/10.36922/an.v1i1.2 Keywords: Alzheimer’s disease; Amyloid-related imaging abnormalities; Edema; Sulcal
Received: November 29, 2021 effusion; Microhemorrhage; Superficial siderosis
Accepted: February 25, 2022
Published Online: March 18, 2022
Copyright: © 2022 Author(s). 1. Introduction
This is an Open Access article According to the latest research report of the World Health Organization (https://www.
distributed under the terms of the
Creative Commons Attribution who.int/health-topics/dementia#tab=tab_1), it is estimated that more than 55 million
License, permitting distribution, people live with dementia worldwide. Notably, dementia is currently the seventh
and reproduction in any medium,
provided the original work is leading cause of death among all diseases, and is one of the major causes of disability
properly cited. and dependency among older adults. Among all types of dementia, Alzheimer’s disease
[1]
Publisher’s Note: AccScience (AD) is the most common and accounts for 60 – 80% of all cases . Although the
Publishing remains neutral with incidence of AD has demonstrated a declining trend in some affluent countries, the
regard to jurisdictional claims in [2-4]
published maps and institutional situation remains less optimistic in developing countries . In China, the number of
[5]
affiliations. AD-affected patients exceeds 9 million , and the socioeconomic losses caused by AD

Volume 1 Issue 1 (2022) 1 https://doi.org/10.36922/an.v1i1.2